lncRNA Blog lncRNA Research and Industry News
Eighty-eight cervical cancer patients, 64 cervical intraepithelial neoplasia patients, 25 breast cancer patients, 25 ovarian cancer patients, and 111 healthy control subjects were enrolled into this study. Researchers at Jiangxi University of Traditional Chinese Medicine measured PVT1 serum level in these participants and PVT1 expression in 20 pairs of cervical cancer tissues and adjacent paired normal tissues by quantitative reverse transcription-polymerase chain reaction. The diagnostic values of serum PVT1 were evaluated by receiver operating characteristic curves analysis.
Serum PVT1 level is significantly increased in cervical cancer patients and correlated with tumor size, clinical stage, and lymph node metastasis of cervical cancer. Serum PVT1 could accurately discriminate cervical cancer patients from cervical intraepithelial neoplasia patients and healthy control subjects, and also discriminate early stage cervical cancer patients from healthy control subjects. But serum PVT1 level is not changed in breast cancer and ovarian cancer patients. Furthermore, serum PVT1 level is positively correlated with tissue PVT1 expression, and could indicate cervical cancer dynamics.
Serum PVT1 levels in CC and CIN patients and its correlation with clinical features
A, Serum PVT1 levels in 88 CC patients, 64 CIN patients, and 86 HC subjects. B, Serum PVT1 levels in CC patients with tumor size < 4 cm or tumor size > 4 cm. C, Serum PVT1 levels in CC patients at different FIGO stages. D, Serum PVT1 levels in CC patients with or without lymph node metastasis. Serum PVT1 levels were measured by qRT-PCR. Results are presented as median with interquartile range. *p < 0.05, ***p < 0.001 by Mann-Whitney U test.
